Skip to main content

Genetically engineered goats could be the key to mass-producing cancer drugs

Could the answer to mass-producing cancer drugs be … genetically modified goats? It might sound kind of crazy, but upon closer inspection, it actually makes a whole lot of sense. The drugs in question, therapeutic mAbs (aka monoclonal antibodies), are used in the treatment of human diseases including cancer. They are commonly produced in large bioreactors using cultured cells from mammals. But this process is extremely expensive, which in turn raises the cost for customers who may desperately need the drugs.

An international team of researchers led by Goetz Laible, a a senior scientist for New Zealand-based AgResearch and an animal scientist at the University of Auckland, is setting out to make these drugs in a different way — by using genetically engineered goats to produce them in their milk.

“To generate goats that are capable of producing the mAb in their milk, we first introduced the genes holding the information for the mAb into the genome of goat cells,” Laible told Digital Trends. “From such goat cells, live goats were generated using the cloning technology that was developed to generate the sheep Dolly. With these additional genes in their genomes, the goats were able to produce the antibody in their milk — but were otherwise normal, healthy animals.”

Goetz and his goats. Goetz Laible

This is not the first time that genetically engineered goats have been used as unlikely manufacturing vessels in the name of science. In 2012, scientists tested the idea of using goats for the production of spider silk in large quantities.

Laible said that this latest study validates the idea that goats could serve as an “excellent platform” for large-scale production of cancer-treatment drugs at a lower cost. In the process, it could help make the drugs, which are used for the treatment of a wide range of human diseases, available more widely. It may also have additional benefits.

“The scale of production is essentially fixed [at present due to ] the size of the bioreactor for mammalian cell cultures, and scaling of production volumes is very limited,” he said. “By contrast, an animal production platform is very flexible. Production volumes can be readily scaled by simply increasing or decreasing the number of production animals.”

The team now plans to undertake additional testing to further demonstrate the safety and effectiveness of anti-cancer treatments manufactured using goats.

A paper describing the research is available to read via the biology preprint server bioRxix.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Elon Musk’s Neuralink now recruiting for first human trials
Everything you need to know about Neuralink

Elon Musk’s Neuralink company has announced that it’s now accepting applications from human subjects willing to have its experimental N1 computer interface implanted in their brain.

Neuralink’s first in-human study, called PRIME (Precise Robotically Implanted Brain-Computer Interface), is encouraging interest from those with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS). They should also be at least 22 years old and have a consistent and reliable caregiver.

Read more
Amazon is hiring a quarter of a million extra workers for the holiday season
A warehouse worker at Amazon.

Eyeing the upcoming holiday rush, Amazon announced on Tuesday that it’s seeking to hire 250,000 warehouse and delivery workers to work alongside its existing team. A bump in the hourly pay rate is also being offered in the hope of encouraging more people to sign up.

The e-commerce giant usually runs hiring campaigns around this time of year to help it manage the huge volume of extra deliveries that come its way as folks jump online to buy gifts and other items during the holiday season.

Read more
NASA’s Artemis moon astronauts suit up for mission practice run
NASA's crew for the Artemis II lunar mission.

The four Artemis II astronauts who will embark on a flyby of the moon in November next year successfully conducted a pre-launch practice run on Wednesday.

In line with launch day procedures, NASA astronauts Christina Koch, Victor Glover, and Reid Wiseman, along with Canadian Space Agency astronaut Jeremy Hansen, started the day by waking up inside the crew quarters at the Neil Armstrong Operations and Checkout Building at the Kennedy Space Center in Florida.

Read more